Bristol-myers Squibb Stock News

Bulls seeking stock trades should focus on relative strength. Here are three stocks itching for new highs as the market sinks.

We provide a summary of upcoming ex-dividend dates in a quick reference table.

Bristol Myers Squibb (BMY) closed at $69.24 in the latest trading session, marking a +0.54% move from the prior day.

Look for companies with high free cash flow and built-in inflation protection.

A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.

Bristol Myers Squibb Co (NYSE: BMY ) and Nektar Therapeutics (NASDAQ: NKTR ) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma patients. The review by an independent Data Monitoring Committee (DMC) suggested that the study did … Full story available on Benzinga.com

Adding Nektar''s most drug to Bristol Myers'' Opdivo didn''t improve outcomes for melanoma patients — leading NKTR stock to crash Monday.

By now you've gotten the memo that it's time to own value stocks, since value beats growth when consumer prices and interest rates rise.

Clinical-stage biotech, Nektar Therapeutics <> has lost more than 53% in the pre-market Monday after the company and Bristol Myers Squibb (BMY) announced a major setback for its…

Cancer drug bempeg was an important one for biotech Nektar and its partner Bristol Myers Squibb.

Nektar Therapeutics (NASDAQ: NKTR ) is trading significantly lower Monday morning after the company''s Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY ), did not meet its primary endpoint. Following a review of the study for efficacy and … Full story available on Benzinga.com

Bristol Myers Squibb (BMY) and Nektar Therapeutics'' (NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line…

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo 

VOO and other S&P 500 index funds report data that can lag for as much as two months behind. We compare metrics of VOO as of January 31, 2022 and those of SPY now to see how they differ.

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) was among the biggest gainers of the week. The stock moved out of penny stock territory after the company announced UnitedHealth Incorporated (NYSE: UNH ) added Eysuvis 0.25% as a covered brand on its commercial formularies, effective March 2022. China-based biopharma companies Zai Lab Ltd. (NASDAQ: ZLAB ), BeiGene Ltd. (NASDAQ: BGNE ) and Hutchmed China Ltd (NASDAQ: HCM ) came under selling pressure after the SEC included these companies in the list of companies facing delisting threat. Here are the key catalysts that could move stocks in the unfolding week: Conferences World Sleep Congress, or WSC, 2022: March 11-16, in Rome, Italy Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (hybrid event): March 13-16 Roth 34th Annual Healthcare Conference: March 14 Oppenheimer Virtual Annual Healthcare Conference: March 15-16 Barclays Global Healthcare Conference: March 15-17, in Miami, Florida AD/PD 2022: International Conference On Alzheimer''s And Parkinson''s Diseases And Related Neurological Disorders: March 15-22, in Barcelona, Spain 1st Annual Needham Virtual Neuroscience Forum: March 16 Guggenheim Virtual Healthcare Talks - Targeted Protein Degradation Day: March 16 American Society for Clinical Pharmacology & Therapeutics, ASCPT, Annual Meeting: March 16-18 Society of American Gastrointestinal And Endoscopic Surgeons, or SAGES, 2022 Annual Meeting: March 16-19, in Denver, Colorado American Pain Society, or APS, Annual Scientific Meeting: March 17-20, in Scottsdale, Arizona Society of Gynecologic Oncology, or SGO, Annual Meeting on Women''s Cancer: March 19-22, in Phoenix, Arizona European Group for Blood and Marrow Transplantation, or EBMT, Annual Congress: March 19-23, in Prague, Czech Republic PDUFA Dates The Food and Drug …